Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Конверсия неоперабельной стадии рака легкого в операбельную у EGFR-позитивных пациентов на фоне лечения гефитинибом: два клинических случая
Конверсия неоперабельной стадии рака легкого в операбельную у EGFR-позитивных пациентов на фоне лечения гефитинибом: два клинических случая
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Loriot Y, Soria JC, Le Chevalier T. Expanding role of chemotherapy in lung cancer. Ann Oncol 2006; 17 (suppl. 10): x101–7.
2. Chang CH, Chen KY, Young-Xu Y et al. The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung Cancer 2008; 62: 242–52.
3. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007; 58: 95–103.
4. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442–9.
5. Yang CH, Yu CJ, Shih JY et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-smallcell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008; 26: 2745–53.
6. Okamoto T, Maruyama R, Shoji F et al. Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 2005; 47: 85–91.
7. Govindan R, Behnken D, Read W, McLeod H. Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. Ann Oncol 2003; 14: 1330–1.
8. Takamochi K, Suzuki K, Sugimura H et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 2007; 58: 149–55.
9. Kappers I, Klomp HM, Burgers JA et al. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol 2008; 26: 4205–7.
10. Mok T, Wu YL, Thongprasert S et al. Phase III, randomised, openlabel, first-line study of gefitinib (G) vs. carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small cell lung cancer (NSCLC) (IPASS). Ann Oncol 2008; 19 (suppl. 8): viii1.
11. Sirera R, Catot S, Gonzalez-Larriba GL et al. Customizing erlotinib in metastatic non-small sell lung cancer (NSCLC) patients (P) harboring EGFR mutations. Ann Oncol 2008; 19 (suppl. 8): viii90.
12. Altorki N, Heymach J, Guarino M et al. Phase II study of pazopanib (GW786034) given preoperatively in stage I–II non-small cell lung cancer (NSCLC): a proof-ofconcept study. Ann Oncol 2008; 19 (suppl. 8): viii89.
13. Tsuboi M, Kato H, Nagai K et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs 2005; 16: 1123–8.
14. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237–46.
15. Lee KH, Han SW, Hwang PG et al. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-smallcell lung cancer. Jpn J Clin Oncol 2006; 36: 344–50.
2. Chang CH, Chen KY, Young-Xu Y et al. The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung Cancer 2008; 62: 242–52.
3. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007; 58: 95–103.
4. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442–9.
5. Yang CH, Yu CJ, Shih JY et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-smallcell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008; 26: 2745–53.
6. Okamoto T, Maruyama R, Shoji F et al. Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 2005; 47: 85–91.
7. Govindan R, Behnken D, Read W, McLeod H. Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. Ann Oncol 2003; 14: 1330–1.
8. Takamochi K, Suzuki K, Sugimura H et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 2007; 58: 149–55.
9. Kappers I, Klomp HM, Burgers JA et al. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol 2008; 26: 4205–7.
10. Mok T, Wu YL, Thongprasert S et al. Phase III, randomised, openlabel, first-line study of gefitinib (G) vs. carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small cell lung cancer (NSCLC) (IPASS). Ann Oncol 2008; 19 (suppl. 8): viii1.
11. Sirera R, Catot S, Gonzalez-Larriba GL et al. Customizing erlotinib in metastatic non-small sell lung cancer (NSCLC) patients (P) harboring EGFR mutations. Ann Oncol 2008; 19 (suppl. 8): viii90.
12. Altorki N, Heymach J, Guarino M et al. Phase II study of pazopanib (GW786034) given preoperatively in stage I–II non-small cell lung cancer (NSCLC): a proof-ofconcept study. Ann Oncol 2008; 19 (suppl. 8): viii89.
13. Tsuboi M, Kato H, Nagai K et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs 2005; 16: 1123–8.
14. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237–46.
15. Lee KH, Han SW, Hwang PG et al. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-smallcell lung cancer. Jpn J Clin Oncol 2006; 36: 344–50.
Авторы
Е.В.Левченко, В.М.Моисеенко, Д.Е.Мацко, А.Г.Ивлева, А.О.Иванцов, С.М.Яргниан, В.В.Анисимов, И.И.Семионов, Е.Н.Имянитов
Институт онкологии им. Н.Н.Петрова, Санкт-Петербург
Институт онкологии им. Н.Н.Петрова, Санкт-Петербург
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.